A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people'

Trial Details

NCT ID
NCT07223021
Phase
PHASE3
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Fludarabine
  • Cyclophosphamide
  • CAR-T
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Memphis, Tennessee, United States|35.14953,-90.04898
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
  • Patient's weight \> 9 kg at time of lymphodepleting chemotherapy
  • Adequate organ function at time of LD is required and is defined:
  • Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →